However, when NMD reduces the expression of a mutant CFTR protein that has partial activity, it exacerbates the phenotype, so that patients homozygous for the CFTR-W1282X mutation or compound heterozygous for CFTR-W1282X and another CF-causing mutation have poor clinical outcomes. This evidence concerns the gene CFTR and cystic fibrosis.